PT  - JOURNAL ARTICLE
ED  - , 
TI  - Agios Exits Oncology
AID  - 10.1158/2159-8290.CD-NB2021-0303
DP  - 2021 Jan 27
TA  - Cancer Discovery
4099  - http://cancerdiscovery.aacrjournals.org/content/early/2021/01/26/2159-8290.CD-NB2021-0303.short
4100  - http://cancerdiscovery.aacrjournals.org/content/early/2021/01/26/2159-8290.CD-NB2021-0303.full
AB  - Agios Pharmaceuticals, the company behind the only two IDH-targeted drugs on the market and a brain-penetrant IDH inhibitor in late-stage testing for glioma, announced plans to sell its oncology business to Servier for up to $2 billion plus royalties.